[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629214":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":25,"responsibleParty":40,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Fujian Provincial Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"High-risk Population",null,"Participants at high risk of acute myocardial infarction, including individuals with stable angina or unstable angina, with or without silent myocardial ischemia, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.",{"label":13,"type":10,"description":14,"interventionNames":10},"Confirmed Acute Myocardial Infarction Population","Participants with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction, including type 1, 2, 3, 4a, 4b, 4c, and 5 myocardial infarction, as well as myocardial infarction with non-obstructive coronary arteries when applicable, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.",[16],{"name":17,"affiliation":18,"role":19},"Kaiyang Lin, PhD","Fuzhou University Affiliated Provincial Hospital","PRINCIPAL_INVESTIGATOR",[21],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","+86 13559355708","lky7411@sina.com",[26],{"facility":18,"status":10,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Fuzhou","Fujian","350001","China","CN",{"type":33,"coordinates":34},"Point",[35,36],119.30611,26.06139,{"lat":36,"lon":35},[39],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":19,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Kaiyang Lin","Principal Investigator, Department of Cardiology","100629214","prospective-lifespan-cohort-of-myocardial-infarction-100629214",false,"NCT07471763","Prospective Lifespan Cohort of Myocardial Infarction","A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System","Inclusion Criteria:\n\nAge 18 to 74 years\n\nDiagnosed with stable angina, unstable angina, or acute myocardial infarction\n\nFor acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized\n\nDiagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction\n\nWilling to participate and able to provide written informed consent\n\nAble to complete baseline assessment, biospecimen collection, and long-term follow-up\n\nExclusion Criteria:\n\nEnd-stage malignant tumor with expected survival of less than 1 year\n\nSevere hepatic or renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or Child-Pugh class C)\n\nActive autoimmune disease or long-term use of immunosuppressive agents\n\nPregnant or breastfeeding women\n\nInability to provide informed consent or severe cognitive impairment\n\nPrevious participation in another clinical study that may conflict with this project\n\nAny other condition considered by the investigators to make participation inappropriate","ALL","18 Years","74 Years",{"count":54,"type":55},6000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.\n\nThe study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.\n\nThe primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.",[59,60,61],"Acute Myocardial Infarction (AMI)","Stable Angina","Unstable Angina",[63,64,65,66,67,68,69],"prospective cohort","multi-omics","artificial intelligence","risk prediction","precision medicine","acute myocardial infarction","lifespan cohort","NOT_YET_RECRUITING","2026-03-22",{"date":73,"type":74},"2026-03-25","ACTUAL",{"date":76,"type":55},"2026-04-10",{"date":78,"type":55},"2031-04-10",{"name":5,"class":6},1]